Global Conference 2018

Rarely does the biopharma industry see anything like the explosion of activity that is immuno-oncology today. There are currently thousands of agents in development, and millions of possible combinations, which need to be tested if we are to successfully treat most cancers. Massive investments are at stake, enormous acquisitions are underway, and there are limited numbers of patients available to participate in trials. How do we keep the promise of immuno-oncology from jumping off the rails?

View Video


Louise Perkins

Chief Science Officer, Melanoma Research Alliance


Pablo Legorreta

Founder and CEO, Royalty Pharma

Johanna Mercier

President and Head, U.S. Commercial, Bristol-Myers Squibb

Jill O'Donnell-Tormey

CEO and Director of Scientific Affairs, Cancer Research Institute

Antoni Ribas

Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology, University of California Los Angeles

Greg Simon

President, Biden Cancer Initiative

Return to Program Detail